BioInformant

Your Global Leader in Stem Cell Market Research

  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • News
    • Interviews
  • Advertise
  • Shop
  • Company
    • Story
    • Testimonials
    • Submit PR
    • Job Posts
    • Privacy Policy
    • Guarantee
    • Contact
Home » Cell Therapy » CAR-T » Page 2

Why is Healthy Donor Tissue So Important for Cell and Gene Therapies?

June 27, 2019 By Cade Hildreth (CEO)

HemaCare healthy donor

Brad Taylor, PhD and Dominic Clarke, PhD
HemaCare Corporation 8500 Balboa Boulevard Suite 130 Northridge CA 91325

INTRODUCTION

Public discourse on cell and gene therapy is focused on novel approaches to long-established procedures such as bone marrow transplants, as well as on truly innovative treatments such as cancer immunotherapy and stem cell therapy for autoimmune disorders and other serious ailments. Positive clinical trial results and the demonstrated success of advanced therapies such as Kymriah® and Yescarta® are fueling a sense of excitement on what could be accomplished with these medicines—and driving a significant increase in the number of cell therapies in the clinical trial pipeline. As of last year, there were nearly 300 different cell and gene therapies in development, and that number is on target to grow.[1] [Read more…]

4.4 / 5 ( 13 votes )

Filed Under: CAR-T, Cell Therapy Tagged With: HemaCare

New Frontiers in Gene-Editing and Stem Cell Innovation – Interview with Dr. Chen-Tsai of Applied StemCell

June 15, 2019 By Cade Hildreth (CEO)

Applied StemCell, Inc.

Applied StemCellI had the honor of interviewing Dr. Ruby Yanru Chen-Tsai, Chief Scientific Officer and Co-founder of Applied StemCell Inc. (ASC), a fast growing biotechnology company in Milpitas, California. Specializing in gene-editing technologies and stem cell innovation, ASC offers an optimized series of tools for basic research study, drug discovery, bio-processing, bio-production and preclinical applications.

In this fascinating interview, we discuss Dr. Yanru Chen-Tsai’s impressive background, ASC’s unique product portfolio, its TARGATT™ gene editing technology, and the company’s future trajectory. [Read more…]

4.8 / 5 ( 19 votes )

Filed Under: CAR-T, Interviews, Stem Cells Tagged With: Applied StemCell, gene editing, interview

Cellectis Secures 82,000 Sq Ft Manufacturing Facility in Raleigh to Compliment Paris Facility

March 19, 2019 By Cade Hildreth (CEO)

CellectisCellectis, a leading French biopharmaceutic company, has signed a lease agreement for an 82,000 sq. ft. manufacturing facility in Raleigh, North Carolina, to complement its existing 14,000 sq. ft. manufacturing facility in Paris, France.

Located at 2500 – 2540 Sumner Boulevard in Raleigh, NC, the new USA facility is owned by Equus Capital Partners and will be used for clinical and commercial production of Cellectis’ leading allogeneic UCART products.

Importantly, the decision will combine the capabilities of Cellectis’ two facilities to advance its manufacturing processes and prepare for potential commercialization of its UCART products in the future. [Read more…]

2.5 / 5 ( 4 votes )

Filed Under: CAR-T, News Tagged With: CAR-T, Cellectis, UCART

Gilead Gets Notice of Compliance for Yescarta™ from Health Canada

February 24, 2019 By Cade Hildreth (CEO)

Yescarta approved in Canada

Yescarta™ is positioned to join Kymriah™ as the second chimeric antigen receptor T cell (CAR-T) therapy to achieve regulatory approval in Canada, based on exciting news released this month from Gilead Sciences Canada. [Read more…]

5 / 5 ( 4 votes )

Filed Under: CAR-T Tagged With: CAR-T, Gilead, novartis, Yescarta

Australian TGA Approves Novartis’ Kymriah® CAR-T Therapy for Two Blood Cancers

December 31, 2018 By Cade Hildreth (CEO)

CAR-T Australia

Kymriah® (tisagenlecleucel), CAR-T therapy from Novartis, receives TGA approval for treating two aggressive blood cancers

  • Kymriah® is an immunocellular therapy that is a one-time treatment manufactured individually for each patient using the patient’s own T cells, genetically reengineered and programmed to recognise and destroy cancer cells.
  • Kymriah® is approved for the treatment of relapsed or refractory patients with paediatric B-cell acute lymphoblastic leukaemia (ALL) and adult diffuse large B-cell lymphoma (DLBCL)[1]
  • Kymriah® could be a treatment option for about 50 paediatric and young adult ALL patients and 420 adult DLBCL patients who relapse or do not respond to initial therapy[2]
  • Kymriah® is the only chimeric antigen receptor T cell (CAR-T) therapy to receive TGA approval in Australia[1]

[Read more…]

4.5 / 5 ( 11 votes )

Filed Under: CAR-T, News, Press Releases Tagged With: CAR-T, Kymriah, novartis

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 7
  • Next Page »

Let’s Get Social

  • Facebook
  • Twitter
  • Instagram
  • Pinterest
  • LinkedIn

Nanocellect

Aspire

Marathon Products

Cellevate

Perinatal Stem cell Society

Menu
  • Blog
  • News
  • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • US Cord Blood and Cord Tissue Storage Rates Rates of U.S. Cord Blood and Cord Tissue Storage - Historical and Projected $197
  • Global Database of Stem Cell Therapy Companies - Featuring 100+ Companies $39
  • Defining the Future of the Stem Cell Industry: Interviews with Stem Cell Executives $197 $97

Featured Posts

Adaptimmune RMAT

Adaptimmune Receives RMAT Designation for ADP-A2M4 for Synovial Sarcoma

Feature | CAR-T Cell Therapy | What You Need To Know

What is CAR-T Cell Therapy? | CAR-T Definition

CAR T Cell Therapy

CAR-T Cell Therapy Attracts Vast Sums of Money

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Disclaimer

Copyright © 2019 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.